Fig. 6
From: Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
REV7-deficiency inhibited oxaliplatin-resistant HT29 xenograft tumor growth in vivo. a Photograph of inoculated tumors excised at day 15. HT29 Oxa-R and HT29 Oxa-R-KO tumors with or without oxaliplatin treatment were evaluated in this analysis. b Growth curve of inoculated tumors. Variation is indicated and presented as mean ± SEM. c Weight of inoculated tumors excised at day 15. ns: not significant; ***p < 0.001. The p-values were calculated by using by one-way ANOVA. Variation is indicated and presented as mean ± SEM. d Body weight of the mice measured post-drug treatment. No significant variation was detected. The statistical analysis of cell viability was calculated by using two-way ANOVA